--- title: ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) nct_id: NCT00071188 overall_status: COMPLETED phase: PHASE2 sponsor: Genzyme, a Sanofi Company study_type: INTERVENTIONAL primary_condition: Carcinoma, Non-Small-Cell Lung countries: United States, Finland, France, Germany, India, Italy, South Africa, Spain, Thailand canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00071188.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00071188" ct_last_update_post_date: 2016-08-25 last_seen_at: "2026-05-12T07:01:25.785Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) **Official Title:** A Randomized, Partially Blinded, Phase II Study to Assess the Safety, Tolerability and Efficacy of ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) **NCT ID:** [NCT00071188](https://clinicaltrials.gov/study/NCT00071188) ## Key Facts - **Status:** COMPLETED - **Phase:** PHASE2 - **Study Type:** INTERVENTIONAL - **Lead Sponsor:** Genzyme, a Sanofi Company - **Conditions:** Carcinoma, Non-Small-Cell Lung - **Start Date:** 2004-02 - **Completion Date:** 2007-10 - **CT.gov Last Update:** 2016-08-25 ## Brief Summary The purpose of the run-in phase of this study is to determine the appropriate and tolerable dose of ZD6474 (200mg or 300mg) to be administered in combination with paclitaxel and carboplatin in subjects with previously untreated locally advanced or metastatic NSCLC. This phase of the trial is closed to enrollment. The purpose of the randomized phase of this study is to determine the efficacy of ZD6474 alone versus that of ZD6474 in combination with paclitaxel and carboplatin versus that of paclitaxel and carboplatin alone in subjects with previously untreated locally advanced or metastatic NSCLC. This phase of the trial is closed to enrollment. ## Eligibility - **Minimum age:** 18 Years - **Sex:** ALL - **Healthy Volunteers:** No ``` Inclusion Criteria: * Signed informed consent * 18 years or older * Histologically or cytologically confirmed locally advanced or metastatic NSCLC * No prior chemotherapy/biological therapy/radiation therapy * One or more measurable lesions * Life expectancy more than 12 weeks Exclusion Criteria: * Brain metastases or spinal cord compression * Currently active skin disease * History of significant hemoptysis * Abnormal blood chemistry * Cardiac abnormalities * Recent significant cardiac event * Coexisting malignancies ``` ## Interventions - **ZD6474** (DRUG) - **Paclitaxel** (DRUG) - **Carboplatin** (DRUG) ## Locations (34) - Research Site, Concord, California, United States - Research Site, Los Angeles, California, United States - Research Site, Chicago, Illinois, United States - Research Site, Boston, Massachusetts, United States - Research Site, St Louis, Missouri, United States - Research Site, Providence, Rhode Island, United States - Research Site, Nashville, Tennessee, United States - Research Site, Austin, Texas, United States - Research Site, Houston, Texas, United States - Research Site, Lubbock, Texas, United States - Research Site, Norfolk, Virginia, United States - Research Site, Seattle, Washington, United States - Research Site, Helsinki, Finland - Research Site, Turku, Finland - Research Site, Besançon, France - Research Site, Lille, France - Research Site, Strasbourg, France - Research Site, Essen, Germany - Research Site, Frankfurt, Germany - Research Site, Mainz, Germany - Research Site, Ulm, Germany - Research Site, Pune, India - Research Site, Milan, Italy - Research Site, Orbassano, Italy - Research Site, Cape Town, South Africa - Research Site, Johannesburg, South Africa - Research Site, Panorama, South Africa - Research Site, Parkland, South Africa - Research Site, Pretoria, South Africa - Research Site, Barcelona, Spain - Research Site, Madrid, Spain - Research Site, Málaga, Spain - Research Site, Pamplona, Spain - Research Site, Chiang Mai, Thailand ## Recent Field Changes (last 30 days) - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.research site|concord|california|united states` — added _(2026-05-12)_ - `locations.research site|los angeles|california|united states` — added _(2026-05-12)_ - `locations.research site|chicago|illinois|united states` — added _(2026-05-12)_ - `locations.research site|boston|massachusetts|united states` — added _(2026-05-12)_ - `locations.research site|st louis|missouri|united states` — added _(2026-05-12)_ - `locations.research site|providence|rhode island|united states` — added _(2026-05-12)_ - `locations.research site|nashville|tennessee|united states` — added _(2026-05-12)_ - `locations.research site|austin|texas|united states` — added _(2026-05-12)_ - `locations.research site|houston|texas|united states` — added _(2026-05-12)_ - `locations.research site|lubbock|texas|united states` — added _(2026-05-12)_ - `locations.research site|norfolk|virginia|united states` — added _(2026-05-12)_ - `locations.research site|seattle|washington|united states` — added _(2026-05-12)_ - `locations.research site|helsinki||finland` — added _(2026-05-12)_ - `locations.research site|turku||finland` — added _(2026-05-12)_ - `locations.research site|besançon||france` — added _(2026-05-12)_ - `locations.research site|lille||france` — added _(2026-05-12)_ - `locations.research site|strasbourg||france` — added _(2026-05-12)_ - `locations.research site|essen||germany` — added _(2026-05-12)_ - `locations.research site|frankfurt||germany` — added _(2026-05-12)_ - `locations.research site|mainz||germany` — added _(2026-05-12)_ - `locations.research site|ulm||germany` — added _(2026-05-12)_ - `locations.research site|pune||india` — added _(2026-05-12)_ - `locations.research site|milan||italy` — added _(2026-05-12)_ - `locations.research site|orbassano||italy` — added _(2026-05-12)_ - `locations.research site|cape town||south africa` — added _(2026-05-12)_ - `locations.research site|johannesburg||south africa` — added _(2026-05-12)_ - `locations.research site|panorama||south africa` — added _(2026-05-12)_ - `locations.research site|parkland||south africa` — added _(2026-05-12)_ - `locations.research site|pretoria||south africa` — added _(2026-05-12)_ - `locations.research site|barcelona||spain` — added _(2026-05-12)_ - `locations.research site|madrid||spain` — added _(2026-05-12)_ - `locations.research site|málaga||spain` — added _(2026-05-12)_ - `locations.research site|pamplona||spain` — added _(2026-05-12)_ - `locations.research site|chiang mai||thailand` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT00071188.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT00071188* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*